Why there is no single number
A tablet’s price moves with its dose, your insurance, and where it is dispensed. Treat any figure you see online, including ours, as a starting point for a real quote rather than a promise.
The PinwellRx figure, and what sits inside it
Foundayo is a brand product dispensed through the manufacturer and participating pharmacies rather than through PinwellRx. Pricing there is set by those channels, and delivery. There is no separate consultation fee, and you see the price before you pay anything.
The manufacturer’s channels
Lilly sells directly to self-pay patients and runs a commercial savings card for people with employer insurance. Depending on your coverage, one of those may beat any telehealth price, which is why we check before you are charged rather than after.
Approval status for every brand product is verifiable in Drugs@FDA.
Medicare and insurance
Coverage is changing quickly. Some Medicare Part D plans have begun covering it with a capped monthly cost for eligible patients. If you carry insurance of any kind, let us run it; the answer is sometimes better than the cash price.
The honest comparison
When you compare prices across services, compare the whole package: medication, clinician time, follow-up, and shipping. A low headline number that bills the visit separately is not a low price. See the 30-second film answers for this medication.
Why orforglipron is different from every GLP-1 before it
Orforglipron is a non-peptide, small-molecule GLP-1 receptor agonist. That single structural fact is the whole story. Because it is not a peptide, it is not destroyed by digestion the way semaglutide is, so it needs no absorption enhancer and no empty-stomach protocol: it can be taken at any time of day, with or without food. It reaches the same GLP-1 receptor as the injectables, producing the same class of effects on insulin release, gastric emptying, and satiety signalling. It is not oral tirzepatide, and it is not related to tirzepatide: it acts on GLP-1 only, not on GIP. Is there an oral tirzepatide addresses that confusion directly. Orforglipron was approved by FDA in 2026.
How it compares to what you may already know
The clinically useful comparison is convenience against route. Against oral semaglutide, orforglipron’s advantage is the absence of dosing restrictions, a direct consequence of its small-molecule structure. Against the injectables, it is a daily tablet rather than a weekly shot, which some people prefer and others do not. The ATTAIN programme published in the New England Journal of Medicine reported the trial results for orforglipron; those findings describe the studied product at studied doses and are cited here as published science rather than as a prediction for any individual. Side effects reported are the familiar GLP-1 class picture, predominantly gastrointestinal. Foundayo versus Zepbound compares across routes.
What to expect in the first weeks
Because orforglipron acts on the GLP-1 receptor, the effects people describe early are the familiar class picture: appetite arriving later, meals feeling smaller, and digestive effects that tend to cluster around dose changes. It is a daily tablet, so consistency of timing is a habit question rather than a pharmacological requirement. Report severe or persistent abdominal pain, vomiting that prevents you keeping fluids down, or any reaction that does not settle, rather than waiting for a scheduled check-in. Individual results vary and no result is guaranteed.
What a clinician weighs before prescribing
Approval of a medication does not mean it suits everyone. A clinician reviews your history for pancreatitis, gallbladder disease, thyroid conditions, gastrointestinal motility disorders, pregnancy or plans to conceive, and other medications that interact with delayed gastric emptying. They also consider whether a daily tablet is realistic for you. Declining to prescribe is a legitimate outcome of an honest evaluation, and no payment or intake submission entitles anyone to a prescription.
Your intake goes to a licensed clinician, not an algorithm.
Frequently asked questions
Does insurance cover Foundayo?
Coverage varies widely by plan and is often restricted for weight management. Check directly with your own plan administrator; PinwellRx does not bill insurance.
What is the cash price?
Brand pricing is set by the manufacturer and the dispensing pharmacy, not by PinwellRx. You see the full price before you pay, with no insurance claim involved.
Is there a manufacturer savings program?
Manufacturers sometimes offer savings programs for brand products. Eligibility rules are set by the manufacturer, so check their official site.
Why is a brand tablet priced differently from a compounded option?
Brand products carry FDA approval, clinical trial programs and manufacturer pricing. Compounded preparations are not FDA-approved and are priced by the compounding pharmacy.
Is Foundayo the same as oral tirzepatide?
No. Foundayo contains orforglipron, a non-peptide small-molecule GLP-1 receptor agonist. It acts on GLP-1 only, not GIP, and is unrelated to tirzepatide. There is no FDA-approved oral tirzepatide.
How do you take Foundayo?
It is a once-daily tablet and, because it is not a peptide, it does not require an empty stomach or a waiting period. Follow the instructions supplied with your prescription.
Get the real number for you
We check your insurance and the savings card before you pay anything. Rx only.
Rx only. A licensed clinician decides whether treatment is appropriate and may determine that no treatment, or a different treatment, is right for you. Compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing. Individual results vary.
Sources
Clinical trials listed below evaluated FDA-approved products at the doses studied. They are cited as published science, not as evidence about any compounded preparation, which is not FDA-approved and has not been evaluated by FDA for safety, effectiveness, or quality.
- ManufacturerFOUNDAYO (orforglipron) US prescribing information. Eli Lilly and Company, 2026
- FDA databaseFDA: Drugs@FDA record for orforglipron
- JournalATTAIN: orforglipron clinical trial programme (NEJM)
Spotted something inaccurate? Report an error – corrections are logged per our editorial standards.
More on Foundayo (Orforglipron)
Same medication, different question.
